Keywords: topotarget, savene, sees, strong, ph, i/ii, data

TopoTarget's Savene sees strong Ph I/II data

Article | 04 July 2005

Print This

Danish drugmaker TopoTarget AS says that Savene (dexrazoxane) has demonstrated a 97% success rate in a multicenter Phase II/III trial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in